Strategic acquisitions and cooperation of pharmaceutical raw materials
Posted by tracy ma on Wednesday, December 21, 2011
Under: pharmaceutical raw materials
Years ago, people pay more attention to their internal or rationalization of resources within the industry about resource allocation, and in that time they maybe did not have a mind that today's resources have been at great speed and cover a very wide latitude on earth, and every corner of the global human resource matching is simply amazing for their insight on the physical properties of the deep. In the pharmaceutical and chemical industry in recent years, this pair is the globalization of resources reflecting a trend of ideas, unprecedented international cooperation in strategic acquisitions and strong, and even suggested that international mergers and acquisitions and cooperation has become the current development of the industry's leading pharmaceutical characteristics. Mergers and acquisitions in the worldwide promotion and cooperation, some pharmaceutical and chemical raw material medicine global supply chain has been formed or are being built in the pharmaceutical industry will have a huge impact.
At present, the flow of resources from the macro point of view, strategic acquisitions and international co-operation generally has two direction: First, by the American and European countries to the major producers of bulk drugs in developing countries initiated merger or partnership led initiative to set up its supply chain in Asia ; First, Resveratrol the major producers of bulk drugs in developing countries to developed European countries co-sponsored acquisitions or directly regulate the market in the form of its downstream product chain and marketing network.
The first direction is what we usually call "raw material drug production shift", for this transfer, China's raw material drugs industry have today's prosperity. And technology popularization, product quality pass, has a cost advantage, these three conditions, once mature, European and American countries to API supply chain to Asia became inevitable. In operation, the United States and Europe are usually two ways: one is the raw material and drug suppliers in Asia to sign supply agreements, purchase products directly, or contract manufacturing. In pharmaceutical raw materials in China and India is very common in this model. The other is through mergers and acquisitions, etc., directly in China and India to set up factories in countries with lower production costs of production. This direct control of factory production methods is mainly due to three considerations: First, the formation of the more stable low-cost supply chain, the second is to reduce the transaction costs, the three full use of special local policy environment. Relative to the first direction, second direction opposite on the expression of the will, which reflect a developing country pharmaceutical companies take the initiative to enter the European and American market trends. Among Indian and other Asian drug producing countries of pharmaceutical raw materials fledgling enterprises when it does not meet U.S. and European companies in the passive as a part of the supply chain, they want their advantage in the international market can work more effectively, hoping to reverse in the U.S. and European markets set up their own marketing network. In this direction, India's pharmaceutical companies are doing better. Source:http://www.cospcn.com
At present, the flow of resources from the macro point of view, strategic acquisitions and international co-operation generally has two direction: First, by the American and European countries to the major producers of bulk drugs in developing countries initiated merger or partnership led initiative to set up its supply chain in Asia ; First, Resveratrol the major producers of bulk drugs in developing countries to developed European countries co-sponsored acquisitions or directly regulate the market in the form of its downstream product chain and marketing network.
The first direction is what we usually call "raw material drug production shift", for this transfer, China's raw material drugs industry have today's prosperity. And technology popularization, product quality pass, has a cost advantage, these three conditions, once mature, European and American countries to API supply chain to Asia became inevitable. In operation, the United States and Europe are usually two ways: one is the raw material and drug suppliers in Asia to sign supply agreements, purchase products directly, or contract manufacturing. In pharmaceutical raw materials in China and India is very common in this model. The other is through mergers and acquisitions, etc., directly in China and India to set up factories in countries with lower production costs of production. This direct control of factory production methods is mainly due to three considerations: First, the formation of the more stable low-cost supply chain, the second is to reduce the transaction costs, the three full use of special local policy environment. Relative to the first direction, second direction opposite on the expression of the will, which reflect a developing country pharmaceutical companies take the initiative to enter the European and American market trends. Among Indian and other Asian drug producing countries of pharmaceutical raw materials fledgling enterprises when it does not meet U.S. and European companies in the passive as a part of the supply chain, they want their advantage in the international market can work more effectively, hoping to reverse in the U.S. and European markets set up their own marketing network. In this direction, India's pharmaceutical companies are doing better. Source:http://www.cospcn.com